Introduction
cycle progression (Matuoka et al., 1993) .
Oncogenic activation of RTKs results in deregulated Growth factors and cytokines regulate a wide variety of kinase activity leading to constitutive autophosphorylation biological activities critical for the development, maintenthereby providing potential binding sites for immediate ance and growth of multicellular organisms. Many of downstream effectors. Ras has been shown to be required these events, including cell growth and differentiation, are for transformation mediated by a number of tyrosine coordinated through the interaction of these soluble factors kinases (Smith et al., 1986; Stacey et al., 1991) . However, with cell surface receptors having intrinsic tyrosine kinase little is known about how oncogenic RTKs couple to Ras. activity. Accordant with their importance in cell growth, This is especially relevant for those oncogenic tyrosine many receptor tyrosine kinases (RTKs) were initially kinases that, because of structural alterations such as identified as oncogenes or subsequently found to be deletions or rearrangements, are no longer integral memactivated in a number of transformed states (Aaronson, brane proteins. Recent evidence indicates that such onco-1991). Constitutive activation of RTKs can occur through a proteins do in fact interact with many of the same adaptor variety of mechanisms that mimic ligand-induced receptor dimerization and activation (Lemmon and Schlessinger, proteins that their normal counterparts do, including Grb2 (Pendergast et al., 1993; Borrello et al., 1994; Crowe et al., 1994; Ponzetto et al., 1994; Puil et al., 1994; Fixman et al., 1995) . The potential importance of this interaction in oncogenesis is supported by the observation that mutations that eliminate Grb2 binding impair the transforming potential of these oncogenes (Pendergast et al., 1993; Borrello et al., 1994; Crowe et al., 1994; Ponzetto et al., 1994; Puil et al., 1994; Fixman et al., 1995) . Moreover, Grb2 was shown to be overexpressed in a number of human breast cancer lines and this was correlated with an increase in complex formation with Sos (Daly et al., 1994) . The Tpr-Met oncoprotein is the oncogenic version of the Met receptor tyrosine kinase, the receptor for Hepatocyte Growth Factor/Scatter Factor (HGF/SF). The oncoprotein has sustained a deletion of the extracellular and transmembrane domains and is thus rendered ligand-independent. In addition, due to a genomic rearrangement novel sequences at the C-terminus derived from another locus (Tpr) encode 142 novel amino acids fused in-frame with the Met kinase domain, generating a hybrid p65 Tpr-Met Fig. 1 . Structure, expression and association of Grb2 mutants with oncoprotein (Park et al., 1986) . The Tpr-Met protein Sos. (A) Schematic representation of the structure of the wild type retains kinase activity, which is required for its ability to Grb2 and the two SH3 deletion mutants. (B) and (C) Exogenously transform fibroblasts and is constitutively phosphorylated expressed Grb2 mutants were immunoprecipitated with anti-HA antibodies from lysates prepared from cell populations expressing the on tyrosine residues in vivo (Rodrigues and Park, 1994a) .
Tpr-Met oncoprotein following transfection with Grb2 expression
The N-terminal Tpr sequence includes a leucine zipper vectors and selection in hygromycin. Immunoprecipitates were run on region that is required for the ability of the Tpr-Met promote constitutive dimerization of Tpr-Met in the absence of ligand stimulation (Rodrigues and Park, 1993) . A tyrosine residue (Y489) in the C-terminus of Met serves association with the exchange factor Sos, we were interested to determine whether binding of the Grb2-Sos complex as a binding site for Grb2 as well as the p85 subunit of PI-3 kinase and is required for efficient transformation by is required for transformation by the Tpr-Met oncoprotein.
To address this question, SH3 deletion mutants of Grb2 the Tpr-Met oncoprotein (Ponzetto et al., 1994; Fixman et al., 1995) .
were used to disrupt this complex in cells expressing the Tpr-Met oncoprotein. To determine whether the activation of the Ras/MAP kinase pathway through binding of Grb2 is necessary and The Grb2 protein consists of an SH2 domain flanked on both sides by SH3 domains. Mutants of Grb2 were sufficient to transmit an oncogenic signal, dominantnegative mutants of Grb2 containing deletions of either created by deletion of either the N-terminal or C-terminal (N-SH3 or C-SH3) SH3 domains and the addition of a SH3 domain were used to revert Tpr-Met transformed fibroblasts. Cell clones overexpressing these mutant Grb2 hemagglutinin tag ( Figure 1A ). Mutant Grb2 cDNAs were introduced into a Fischer Rat 3T3 cell line, Tpr-Met-1, molecules were obtained and were found to be morphologically revertant. Expression of a Grb2 mutant as well that expresses the Tpr-Met oncoprotein and has a fully transformed phenotype (Rodrigues and Park, 1993) . Folas a dominant-negative Rac1 impaired the ability of the Tpr-Met oncoprotein to stimulate PI-3 kinase and the Jun lowing transfection of mutant cDNAs and selection in hygromycin, cell populations were examined for expreskinase, providing evidence that Grb2-mediated activation of the JNK/SAPK pathway is required for Tpr-Met transsion of the mutant proteins. Immunoblotting of cell lysates with anti-HA antibodies revealed the presence of proteins formation.
corresponding to the predicted sizes of the Grb2 mutants, demonstrating that these proteins could be stably expressed
Results
in these cells ( Figure 1B ). As predicted, deletion of the SH3 domains was found Grb2 SH3 deletion mutants are expressed in Met transformed fibroblasts but fail to associate with to impair the ability of Grb2 to bind Sos. Grb2 mutants, immunoprecipitated using anti-HA antibodies, were blotSos Mutation of tyrosine Y489 in the C-terminus of Met ted with antibodies to Sos. Despite the expression of equal amounts of mutant Grb2 in lysates as shown by blotting abolishes the ability of the Tpr-Met oncoprotein to associate with the Grb2 adaptor protein and impairs its ability with anti-HA antibodies, only the wild type protein was capable of associating with Sos in vivo ( Figure 1C ). to induce cellular transformation (Ponzetto et al., 1994; Fixman et al., 1995) . However, mutation of this site also reduces association with and activation of phosphatidylGrb2 SH3 deletion mutants inhibit transformation of fibroblasts by the Tpr-Met oncoprotein inositol 3 kinase (PI-3 kinase) as well as association with the tyrosine phosphatase Shp-2 . As
To test the ability of these SH3 deletion mutants to alter the transformed phenotype, Tpr-Met transformants Grb2 has been implicated in the activation of Ras via its overexpressing these mutants were obtained. Individual (HA) tag (Figure 2 ). Consistent with its predicted structure, cell clones were isolated, expanded and further characterthe C-SH3 deletion mutant is not detected by C23 antiized. Figure 2 shows expression of exogenously expressed bodies directed against the C-terminus of Grb2 (Figure 2 ). Grb2 protein in representative cell lines. Total cell lysates Conversely, the N-SH3 deletion mutant is not detected by were blotted with Grb2 antibodies directed against either antibodies which recognize an epitope in the N-terminus the N-or C-SH3 domains. High levels of expression of of Grb2 (Figure 2 ). both the N-and C-SH3 deletion mutants were obtained
To assess the effects of high levels of expression of the ( Figure 2) kinetics. Again the ΔN-SH3 Grb2 mutant had a more dramatic suppressive effect (Figure 3 ). To quantify differ-4). Cells expressing the ΔN-SH3 Grb2 mutant were most impaired in the ability to form foci (30% of the number ences in transforming ability of different cell lines, a focus forming assay was conducted in which cells expressing the of foci obtained with the Tpr-Met-1 cell line) whereas the cells expressing the ΔC-SH3 Grb2 mutant had a very various mutants were mixed with normal untransformed Fr3T3 cells. Focus formation was scored as a percentage modest effect (70% of control) and the cells expressing wild type Grb2 had similar transforming capacity to the relative to the number of foci obtained by mixing Fr3T3 cells with the Tpr-Met-1 cell line. In general cells Tpr-Met-1 cell line ( Figure 4B ). To eliminate the possibility that the observed phenotypic expressing the dominant-negative Grb2 mutants formed fewer, smaller foci with somewhat delayed kinetics ( Figure  changes were due to loss of the Tpr-Met oncoprotein or reduced tyrosine phosphorylation of Tpr-Met in selected cell clones, anti-Met immunoprecipitates from cell clones were blotted with anti-Met and anti-phosphotyrosine antibodies. The results indicate that neither the expression level nor the amount of tyrosine phosphorylation of the Tpr-Met oncoprotein is affected by expression of the mutant Grb2 proteins ( Figure 5 ). Moreover, phosphotyrosine immunoblots of total cell lysates revealed no significant differences in the overall level or pattern of tyrosine phosphorylated proteins in the revertant cell lines ( Figure 5 ).
SH3 deletion mutants of Grb2 bind the Tpr-Met oncoprotein and Shc
The Grb2 SH3 deletion mutants are predicted to retain their ability to bind phosphorylated tyrosine residues but not to signal because of their inability to interact with downstream effector molecules containing proline-rich domains. To formally test this, we assessed the ability of these mutants to associate with the Tpr-Met oncoprotein and other tyrosine-phosphorylated proteins.
To determine whether there were any differences in the type or abundance of tyrosyl-phosphorylated proteins bound to deletion mutants as compared with wild type Grb2, anti-HA immunoprecipitates were probed with antiphosphotyrosine antibodies. Figure 6 shows that a number of phosphoproteins bound to Grb2, including a 52 kDa protein which is consistent with the size of one form of Shc, a 65 kDa protein which corresponds in size to the Tpr-Met oncoprotein and a previously described unknown The 110 kDa protein may correspond to the Gab1 protein 1996; Weidner et al., 1996) . The identity of the 210 kDa protein remains unknown. To confirm that the 52 kDa protein is in fact a form of The JNK/SAPK but not the MAP kinase cascade is blocked by a dominant-negative Grb2 mutant Shc, anti-HA immunoprecipitates were blotted with antiShc antibodies. A prominent 52 kDa protein was observed As Ras is known to activate the MAP kinase signaling cascade (Marshall, 1995) we were interested to know in the Grb2 mutant-expressing cell lines. The 46 and 65 kDa forms of Shc were also observed but were much whether uncoupling of Met from Ras blocked downstream signaling. We therefore determined the phosphorylation less abundant. Similarly, blotting with anti-Met antibodies confirmed the identity of the 65 kDa phosphorylated and activation of MAP kinases in various cell lines. Cell lysates were immunoblotted with a mixture of antibodies protein as the Met oncoprotein and indicates that both mutants as well as the wild type Grb2 bind Met (Figure 6 ).
to the MAP kinases, ERK1 and ERK2. In the parental Fr3T3 cell line only the non-phosphorylated inactive forms The phosphorylation state of Shc is regulated by a number of growth factors ; Rozakisof ERK1 and 2 were detected as determined by a shift in their electrophoretic mobility. In contrast, in MetAdcock et al., 1992; Pronk et al., 1993) and is a direct target for many oncogenic tyrosine kinases (McGlade transformed cells a significant portion of both ERK1 and ERK2 was seen to have a retarded mobility in SDSet al., 1992; Borrello et al., 1994; Crowe et al., 1994; Miloso et al., 1995; Xie et al., 1995) including the PAGE indicative of phosphorylation ( Figure 8A ). When kinase activity was assessed by immunoprecipitating Met oncoprotein . To test whether phosphorylation of Shc was altered in cells expressing ERK1 and measuring its ability to phosphorylate myelin basic protein (MBP), a large increase in kinase activity dominant-negative mutants of Grb2, Shc immunoprecipitates were immunoblotted with anti-phosphotyrosine antiwas seen in the Tpr-Met-1 cell line relative to the parental Fr3T3 cells. Surprisingly, no decrease in the amounts of bodies. The phosphorylation levels in cells expressing the Grb2 were unchanged relative to those of the Tpr-Met-1 shifted ERKs or kinase activity were seen in cells expressing the N-Grb2 deletions ( Figure 8A ). In fact, a cell line, demonstrating that Shc phosphorylation is not sufficient for transformation induced by the Tpr-Met modest increase in kinase activity was observed in these cells indicating that the dominant-negative effect exerted oncoprotein (Figure 7) . by this mutant is unrelated to inhibition of activation of PI-3 kinase activity is inhibited by dominant-negative Grb2 p42 MAPK or p44 MAPK .
Recently, activated PI-3 kinase has been shown to stimulate Recently a number of experimental lines of evidence JNK (Klippel et al., 1996)  shown to activate PI-3 kinase and potentially bind p85 Michiels et al., 1995; Prendergast et al., 1995; Qiu et al., through Y489 prompted examination of PI-3 kinase 1995a,b). Rac1 was shown to be downstream of the Met activity in cells expressing the dominant-negative Grb2 receptor and required for HGF-induced membrane ruffling mutant. Consistent with previous results (Fixman et al., (Ridley et al., 1995) . Recently, Rac1 was shown to activate 1996), potent constitutive PI-3 kinase activity was detected the JNK/SAPK signaling pathway (Coso et al., 1995;  in anti-phosphotyrosine immunoprecipitates from Met Minden et al., 1995) . Thus we were interested in testing transformed cells but not from their untransformed parental whether activation of the JNK/SAPK pathway was altered cell lines ( Figure 9A ). However, in lysates from cells in Met transformed cell lines and whether this is affected expressing the ΔN SH3 dominant-negative mutant of Grb2 by expression of dominant-negative mutants of Grb2. To the amount of PI-3 kinase activity was significantly test this hypothesis, a GST-N-terminal c-Jun fusion protein reduced to~35% of that obtained with immunoprecipitates was used to immunoprecipitate JNK from cell lysates of the Tpr-Met-1 cell line ( Figure 9A ). The ΔC SH3 Grb2 expressing different Grb2 mutants and was used as a mutant retained 65% of the activity obtained with Tprsubstrate in an in vitro kinase assay to measure JNK Met-1, consistent with its transforming capability ( Figure  activity . The results in Figure 8B indicate that JNK activity 4). In contrast to that seen with the anti-phosphotyrosine is enhanced dramatically in cells expressing Tpr-Met when antibodies, very little PI-3 kinase activity was detected compared with normal Fr3T3 cells. In fact the level of with anti-Met antibodies ( Figure 9B ). However, consistent JNK activity in Met transformed cells is comparable with with the results obtained with anti-phosphotyrosine antithat obtained by treatment of Fr3T3 cells with UV, a bodies, the amount of PI-3 kinase activity immunoprecipitpotent activator of JNK. Interestingly, in the cell line ated from lysates expressing the dominant-negative Grb2 expressing the ΔN-SH3 Grb2, JNK activity is significantly mutant was reduced to 25% of that obtained with Tprreduced (4-fold in Figure 8B ). The levels of activity are Met-1 ( Figure 9B ). not reduced to the low levels seen in Fr3T3 cells, consistent
These results suggest that the dominant-negative Grb2 with the incomplete reversion of the transformed phenomutant may prevent association with and/or activation of type seen with this mutant.
PI-3 kinase by the Tpr-Met oncoprotein. To test whether To insure that this observed difference in JNK activity this may occur through a competitive mechanism, the amount of Grb2-associated PI-3 kinase activity was deteris not due to clonal variation, the levels of JNK activity mined in various cell lines. We were able to detect PI-3 were compared between three cell lines expressing differkinase activity associated with exogenously expressed ent amounts of the ΔN-SH3 Grb2 mutant. The ΔN15 clone wild type Grb2 ( Figure 9C ). Interestingly, the ΔN-SH3 expressing the least amount of mutant protein had slightly Grb2 mutant has significantly more associated PI-3 kinase increased levels of JNK kinase activity ( Figure 8C ). activity than does the wild type Grb2 (Ͼ10 fold; Figure  However , as the amount of mutant protein expressed is 9C). Again consistent with its moderate dominant-negative increased, there is a concomitant decrease in JNK kinase effect, the ΔC-SH3 Grb2 mutant had a lower fold activation activity ( Figure 8C ). In contrast, there was a slight relative to the wild type Grb2 ( Figure 9C ). These results elevation in the amount of MAP kinase activity observed suggest that activation of PI-3 kinase may have a role in with increased expression of the ΔN-SH3 Grb2 mutant activation of JNK by the Tpr-Met oncoprotein and that the ( Figure 8C ). Significantly, whereas the ΔN15 clone that dominant-negative Grb2 may associate with and thereby expressed a low level of ΔN-SH3 Grb2 has a fully sequester PI-3 kinase. transformed phenotype indistinguishable from the TprMet-1 cell line, the two cell lines ΔN7 and ΔN11 that A dominant-negative mutant of Rac1 inhibits overexpress the mutant relative to endogenous Grb2 have transformation of fibroblasts by the Tpr-Met a revertant phenotype. Thus, there is a strong correlation oncoprotein between the amount of ΔN-SH3 Grb2 expression, reduced
The above results suggest that activation of the JNK JNK activity and reversion of the transformed phenotype, pathway may in part mediate the transforming ability of indicating that expression of this mutant affects activation the Met oncogene. To assess the role of the JNK pathway of the JNK/SAPK pathway.
in transformation by Met, dominant-negative mutants of To test whether JNK activation is unique to the Tprvarious members of the Rho family of GTP-binding Met oncoprotein or is part of the normal Met signaling proteins were tested in different biological assays. Activresponse, HeLa cells were stimulated with HGF and JNK ation of JNK has recently been shown to activate the Serum activity measured. The results in Figure 8D reveal that Response Element (SRE) through its phosphorylation of the normal endogenously expressed HGF receptor is the transcription factor Elk (Cavigelli et al., 1995; Gille capable of activating JNK upon HGF stimulation. Whitmarsh et al., 1995) . Therefore, we first result suggests that the JNK/SAPK pathway is part of the tested the ability of these mutants to block Tpr-Met normal Met signaling repertoire that is constitutively activation of the SRE driving expression of a luciferase reporter cDNA following transient cotransfection with activated by the oncogenic Tpr-Met. (N17) were isolated and found to be less transformed than cells expressing Tpr-Met alone. 10A). A dominant-negative CDC42 [CDC42(N19)] was somewhat less effective but also significantly inhibited As shown in Figure 10B , Rac1(N17)-expressing cells formed colonies in soft agar that were significantly smaller Tpr-Met activation of the SRE. In contrast, a dominantnegative Rho [Rho(N17)] had little effect on the ability than those formed by Tpr-Met-expressing cells. Tpr-Met cells expressing a dominant-negative Rho or CDC42 did of Tpr-Met to activate an SRE. This result is consistent with the fact that Rac1 and CDC42 are effective activators not appear to be significantly impaired in their transforming potential (data not shown). of JNK whereas Rho is not (Hill et al., 1995) .
Given its ability to potently inhibit SRE activation by To confirm that the inhibition of transforming activity of Met correlated with alteration in JNK activity, kinase the Met oncoprotein we tested the effect of dominant-assays were performed. The results reveal a 2-fold lower level of JNK activity in the cells expressing Rac1(N17) ( Figure 10B ). Control blots confirmed equal expression and phosphorylation of the Tpr-Met oncoprotein as well as expression of Rac1(N17) ( Figure 10B ). Thus, together with the observed effects in Grb2 revertant cell lines, cellular transformation by Tpr-Met oncogene appears to be causally related to activation of the JNK pathway.
Discussion
Based on results obtained with tyrosine mutants of Tpr-Met we hypothesized that binding of the Grb2-Sos complex is one of the principal means by which the Tpr-Met oncoprotein activates Ras and brings about transformation. To test this proposal, dominant-negative mutants of Grb2 capable of binding Tpr-Met but not Sos were introduced into Tpr-Met transformed cells. High levels of overexpression of these mutants were able to revert the transformed phenotype induced by the Tpr-Met oncoprotein ( Figures  3 and 4) . Deletion of the N-SH3 domain of Grb2 had a more profound affect on the transforming ability of the Tpr-Met oncoprotein. This is in agreement with the observation that this domain appears to bind Sos with higher affinity than does the C-SH3 domain (Cussac et al., 1994; Reif et al., 1994; Sastry et al., 1995) and therefore may play a more critical role in propagating signals.
In addition to forming complexes with growth factor receptors, Grb2 can also associate with Shc via its SH2 domain, itself an oncogene . The phosphorylation state of Shc is regulated by a number of growth factors Rozakis-Adcock et al., 1992; Pronk et al., 1993; . Furthermore, Shc phosphorylation is correlated with transformation by many oncogenic tyrosine kinases Borrello et al., 1994; Crowe et al., 1994; Fixman et al., 1995; Miloso et al., 1995; Xie et al., 1995) . However, the levels of phosphorylation of Shc were unaffected by the presence of the dominant-negative Grb2 mutants (Figure 7 ). This is similar to what is observed when Tyr489 is mutated , suggesting that Shc phosphorylation is not sufficient for transformation by the Met oncoprotein although it may contribute to the residual transforming activity observed in these cases.
Unexpectedly, use of the dominant-negative Grb2 JNK but not MAPK is activated in cells transformed by 1995; Qiu et al., 1995a,b) . Importantly, dominant-negative mutants of Rac1 were found to inhibit JNK activation and that oncogene and that JNK activation is absolutely required for this phenotype (Raitano et al., 1995) . In the transformation by tyrosine kinases such as the EGF receptor and the v-src oncogene . case of Met transformed cells both MAP kinase and JNK are activated (Figure 8 ). It is therefore likely that activation Furthermore, a number of exchange factors for Rho family members including Ost and Dbl activate JNK and are of both pathways is required for a fully transformed phenotype and that inhibition of either pathway would be themselves oncogenes. Together these observations suggest that activation of both the MAP kinase and the sufficient to inhibit transformation. More curious is the observation that only one of these pathways is selectively Rac1/JNK pathways are required for efficient oncogenic transformation. Consistent with this hypothesis we inhibited by the ΔN-SH3 Grb2 mutant. This could be related to the fact that different aspects of the transformed observed that a dominant-negative Rac1 is capable of impairing JNK activation and cellular transformation phenotype are more closely associated with different signaling pathways. For example, it has been suggested induced by the Met oncogene (Figure 10 ). Rac1 has been implicated in the process membrane that the activation of MAP kinase is an effector function of Ras distinct from the morphological changes observed ruffling (Ridley et al., 1992) . Ras transformed cells show increased membrane ruffling and microinjection of Ras in transformed cells (Joneson et al., 1996) . The inability to isolate clones that have inhibition of MAP kinase may into normal fibroblasts induces membrane ruffles (BarSagi and Feramisco, 1985; Ridley et al., 1992) . Interesttherefore be related to its essential role in cell growth. Consistent with this notion, we failed to detect significant ingly, HGF induces membrane ruffling, a process that is blocked by microinjection of antibodies to Ras and Rac1 differences in the growth rates of Met transformed cells and those expressing the ΔN-SH3 Grb2 mutant (not (Ridley et al., 1995) . Thus, the ability of dominantnegative mutants of Grb2 to block morphological aspects shown).
Recent evidence suggests that the process of cellular of transformation through inhibition of the Rac1/JNK kinase pathway is in agreement with these observations. transformation by Ras requires a number of cellular events that may involve the participation of multiple signaling How Met couples to Rac1 and JNK is still unclear. One possibility is that Sos, which, in addition to its Ras pathways Michiels et al., 1995; Prendergast et al., 1995; Qiu et al., 1995a,b) .
exchange activity, has a domain with homology to the Rho family of exchange factors, activates Rac1 (Quilliam Ras is essential for transformation by tyrosine kinase oncogenes (Smith et al., 1986; Stacey et al., 1991 Stacey et al., ) et al., 1995 . However, it has not been demonstrated that Sos has any exchange activity toward Rho family and may therefore function as a common component of different signaling cascades. Consistent with this idea is members. Moreover, a membrane-targeted version of Sos that had previously been shown to constitutively activate the isolation of complementary classes of mutations within the effector region of Ras that selectively activate distinct Ras signaling failed to activate JNK (data not shown). Activation of Rho family members may involve coupling signaling cascades in mammalian cells that together are required for transformation Joneson of Ras through an intermediate such as PI-3 kinase, which has been implicated in membrane ruffling (Kotani et al., et al., 1996; . One of these signaling pathways leads to the activation of c-Jun. Trans-1994; Wennstrom et al., 1994; Hawkins et al., 1995) and which has recently been shown to promote the formation formation by oncogenic Ras has been shown to result in increased phosphorylation of c-Jun at the same sites of the GTP-bound form of Rac1 (Hawkins et al., 1995) as well as JNK activation (Klippel et al., 1996) (S.Logan phosphorylated by JNK (Smeal et al., 1992; Westwick et al., 1994) . Moreover, dominant-negative mutants of et al., submitted). Moreover, wortmannin, an inhibitor of PI-3 kinase, has been shown to inhibit EGF-induced Ras block activation of JNK by v-src . Most convincingly, it was recently demonstrated activation of JNK (S.Logan et al., submitted) . As Tyr489 of Tpr-Met serves as the focus for the assembly of a that cells lacking c-Jun are unresponsive to oncogenic forms of Ras (Johnson et al., 1996) . Importantly, it has multiple protein signaling complex which, in addition to Grb2, includes PI-3 kinase, Shc, PLCγ and Shp-2 (Ponzetto been shown that oncogenic Ras activates JNK and c-Jun via a pathway distinct from that of the ERKs (Smeal et al., 1994; Fixman et al., 1995) , the mechanism by which the dominant-negative mutant Grb2 inhibits signaling may et al., 1992; Westwick et al., 1994) .
Recently, JNK kinase has been shown to be part of a involve displacement of components of this complex involved in activation of JNK. PI-3 kinase activity is signaling cascade that includes members of the Rho family (Coso et al., 1995; Hill et al., 1995; Minden et al., 1995;  reduced in cells expressing dominant-negative Grb2 (Figure 9 ). Given the role of PI-3 kinase in activation of Olson et al., 1995) . Interestingly, Rho and Rac1, which were previously shown to be involved in the regulation JNK, one possibility is that the p85 subunit PI-3 kinase is no longer bound to Met in these cells. We have been of the actin cytoskeleton (Ridley et al., 1992) , have recently been implicated in transformation (Khosravi-Far unable to detect association of p85 with the Tpr-Met oncoprotein in vivo and detect very little Met-precipitable et al., 1995 Met-precipitable et al., , 1996 Michiels et al., 1995; Prendergast et al., 1995; Qiu et al., 1995a,b) . Constitutively active mutants PI-3 kinase activity in transformed cells, suggesting that binding of PI-3 kinase to the Tpr-Met oncoprotein may of both Rac1 and Rho potentiate Ras transformation and are themselves weakly transforming (Khosravi-Far et al., be indirect. Interestingly, we detect PI-3 kinase activity associated with exogenously expressed Grb2 mutants 1995 Grb2 mutants , 1996 Michiels et al., 1995; Prendergast et al., 1995) . Conversely, dominant-negative mutants of Rac1 (Figure 9 ). Therefore, one possibility is that Grb2 may bind the proline-rich regions in p85, as has been previously and Rho block transformation by Ras Michiels et al., 1995; Prendergast et al., reported (Wang et al., 1995) , thus sequestering PI-3 kinase
Dominant-negative Grb2 blocks JNK and Met transformation
To test the ability of selected cell lines to form foci, 5ϫ10 domain in a SH3 deletion mutant of Grb2 that can no longer efficiently bind Sos is free to bind the proline-rich here is the first to provide biochemical evidence to demonstrate a link between Met and the JNK pathway.
PI-3 kinase assays
Exact identification of molecules that couple Met to the PI-3 kinase assays were performed as previously described (Hu et al., JNK pathway should provide further insights into the 1993). Briefly, immunoprecipitates were washed three times with PBS mechanisms by which tyrosine kinases promote mitocontaining 1% NP40, twice with 0.5 M LiCl/0.2 M Tris (pH 7.6), twice with TNE (10 mM Tris pH 7.6, 100 mM NaCl, 1 mM EDTA) and twice genesis and cellular transformation.
with 20 mM HEPES pH 7.5, 50 mM NaCl, 5 mM EDTA, 0.03% NP40, 30 mM tetrasodium PP i , 100 μM sodium orthovanadate, 10 μg of aprotinin per ml and 1 mM phenylmethylsulfonyl fluoride. Kinase
Materials and methods
reactions were performed in 50 μl of buffer (20 mM Tris pH 7.6, 75 mM NaCl, 10 mM MgCl 2 ) with 200 μg/ml PI (Avanti), 20 μM ATP, 200 μM Cells and DNA transfection adenosine and 10 μCi of [γ-32 P]ATP for 20 min at room temperature. Fischer rat 3T3 cells were maintained in Dulbecco's Modified Eagle's Reactions were terminated by the addition of 1 N HCl and the lipids Medium (DMEM) supplemented with 10% fetal bovine serum. The extracted with a 1:1 volume of chloroform/methanol. Lipids were isolation of the Tpr-Met-1 cell line has been described previously separated by chromotography in chloroform:methanol:4 M NH 4 OH (Rodrigues and Park, 1993) . Generation of the SH3 deletion mutants of (9:7:2) (by vol) and visualized by autoradiography. Grb2 are described elsewhere (Gishizky et al., 1995) . Transfections of Fischer rat 3T3 cells to generate stable cell lines was carried out using Luciferase assays the calcium phosphate precipitation method.
Forty-eight hours post-transfection, cells were washed with PBS and Antibodies lysed with luciferase lysis buffer (Promega). An aliquot of cleared lysate The Met polyclonal antibody, Ab144 directed against an epitope in the was added to luciferase reaction buffer (25 mM gycylglycine pH 7.8, C-terminus of Met has been described previously (Rodrigues et al., 15 mM MgSO 4 , 1 mM ATP pH 7.0, 0.1 mg/ml BSA and 1 mM DTT). 1991). EL6 is a monoclonal antibody that recognizes an epitope in the D-luciferin (1 mM) was automatically injected into the mixture and SH2 domain of Grb2. The monoclonal antibody that recognizes an activity measured in a luminometer. epitope in the N-terminal SH3 domain of Grb2 was purchased from Transduction Laboratories (Lexington, KY). The C23 antibody is a
